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Abstract
Purpose This study aimed to determine the predictive power
of the DiaRem score following Roux-en-Y gastric bypass to
identify patients who would have diabetes remission at 1 year
in an ethnically diverse population.
Methods We performed a retrospective review of 262 patients
with type 2 diabetes mellitus who underwent RYGB at the
Imperial Weight Centre, UK, from 2007 to 2014. Data was
collected on the parameters required to calculate the DiaRem
score as well as pre- and post-surgical weight and the ethnicity
of the subjects.
Results The studied cohort was ethnically diverse (61.3 %
Caucasian, 10.3 % Asian, 5.3 % black, 2.6 % mixed and
20.6 % other). At 1-year post-surgery, there were significant
reductions in mean weight (133.4 to 94.3 kg) and BMI (46.7
to 33.3 kg/m2). ThemeanHbA1c decreased from 8.2 to 6.1%,
and 32.5 % of the cohort underwent either partial or complete
remission. 67.8 % of the patients that were classified in group
1 of the DiaRem score (most likely to have remission) had
complete remission. However, 22.9 % of the patients predict-
ed to have the least chance of remission had either partial or
complete remission.
Conclusions In this ethnically diverse cohort, the DiaRem
score remains a useful tool to predict diabetes remission in
those that have a low DiaRem score (high chance for remis-
sion) but was more limited in its predictive power in those
with a high DiaRem score (least likely to have remission).
Caution must be used in the application of this model in pop-
ulations other than the US white Caucasian population used to
derive the score.
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Introduction
The incidence of type 2 diabetes mellitus (T2DM) continues
to rise within the UK, driven by the obesity epidemic [1].
Roux-en-Y gastric bypass (RYGB) surgery is currently the
most effective treatment for T2DM resulting in long-term re-
mission in a proportion of patients [2–4]. Whilst considered
cost-effective and safe, the availability of the operation is un-
able tomeet the demand due to the rapidly rising prevalence of
obesity [5, 6]. Furthermore, although RYGB may result in
improvement in obesity comorbidities, not all patients with
diabetes undergo remission. In the context of a health service
with limited resources, a predictive score for the probability of
significant diabetes improvement is required to target surgery
only to those most likely to benefit. Current predictive scores
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include the DiaRem [7] and the ABCD scores [8]. The
DiaRem score has been validated in three different popula-
tions: USA [7, 9], Taiwan [8] and Brazil [10]. However, no
external validation has been performed in the UK population.
To address this gap, we performed a retrospective study within
a tertiary bariatric service in London.
Methods
We conducted a retrospective review of the records of patients
with both obesity and T2DM who had undergone RYGB sur-
gery at Imperial Weight Centre between 2007 and 2014.
Preoperative data was collected to calculate the DiaRem score
which requires the following: patient’s age, preoperative
HbA1c, preoperative use of insulin and other diabetic medi-
cations [7]. In addition, patient demographics including eth-
nicity were recorded. Ethnic categorization was based on
codes devised by the Office for National Statistics. There are
five main categories: ‘white’, ‘mixed’, ‘Asian or Asian
British’, ‘Black or Black British’ and ‘other ethnic groups’.
In this system, subjects who originate from India, Pakistan and
Bangladesh are classified as ‘Asian’ whilst patients who iden-
tify themselves as Chinese are placed in the ‘other ethnic
group’. Postoperative data was collected at 1-year post-sur-
gery to determine remission of diabetes: fasting glucose,
glycated haemoglobin (HbA1c) and diabetic medication.
Remission of diabetes was defined as per the American
Diabetes Association (ADA) criteria [11]. Complete re-
mission requires a fasting glucose below 5.6 mmol/l and
an HbA1c below 6.0 % for 1 year, without the use of any
diabetic medication. Partial remission is defined as a
fasting glucose between 5.6 and 6.9 mmol/l and an
HbA1c between 6.0 and 6.5 % for the duration of 1 year,
in the absence of any diabetic medication. The patients
were therefore analysed for the presence or absence of
diabetes remission at least 12 months after surgery.
Patients were divided into five groups by DiaRem
score: group 1 (0–2), group 2 (3–7), group 3 (8–12),
group 4 (13–17) and group 5 (18–22). In Still et al. [7],
a lower DiaRem score predicted a higher chance of dia-
betes remission, with 88 % of patients in group 1 having
partial or complete remission and only 2 % of patients in
group 5 having partial or complete remission.
Statistical Analysis
Data was analysed using GraphPad Prism 6.0 h (GraphPad,
San Diego, CA). Paired student’s t tests were used to compare
pre- and post-surgical variables within our study population,
whilst an unpaired t test was used to compare this study pop-
ulation with other validated cohorts. A comparison of medi-
cation pre- and post-surgery was performed using a Chi-
square test. A Cochran-Armitage test was used to test for
significance in the association between trend of diabetes re-
mission and DiaRem score.
Results
Patient Characteristics
Two hundred sixty-two patients with T2DM and obesity
underwent RYGB surgery at the Imperial Weight Centre be-
tween 2007 and 2014. The preoperative demographics are
shown in Table 1. There was a higher prevalence of female
patients (59.9 %). The mean age (±SD) of the population was
51.0 ± 9.5 years and the mean (±SD) preoperative weight was
133.4 ± 23.4 kg. With reference to glycaemic control, the
mean (±SD) preoperative HbA1c was 8.2 ± 1.8 %. The most
common ethnicity was Caucasian (61.1 %) followed by Asian
(10.3 %). At 1-year post-surgery, there were statistically sig-
nificant reductions in both weight and HbA1c.
DiaRem Scoring and Diabetes Remission
At 1 year, complete remission was seen in 85 patients (27.9%)
while partial remission was seen in a further 12 (4.6 %).
67.8 % of those with DiaRem score 0–2 had complete or
partial remission, 38.5 % of those with score 3–7, 27.9 % of
those with score 8–12, 9.5 % in those with score 13–17 and
22.9 % in those with score 18–22 (Table 2).
Discussion
The DiaRem score is a simple, clinically based scoring system
to predict the remission of diabetes following bariatric surgery.
However, in our UK-based population, the predictive power
of the DiaRem score was reduced (Table 2). Only 68 % of the
patients in our cohort with DiaRem score of 0–2 experienced
remission (completely or partially) compared to 88 % in the
US study [7]. In contrast, at scores of 18–22, 23 % of our
patients experienced remission (completely or partially) com-
pared to 2 % in the US study. Validation of the DiaRem score
in other populations has revealed similar limitations. Lee et al.
studied a Taiwanese population and found also that >25 % of
their patients with the highest DiaRem scores experienced
complete remission despite being predicted to have no chance
of complete remission according to the Still et al. data [8]. A
similar finding in another US cohort by Aminian et al. showed
that 20 % of patients with DiaRem scores 18–20 had either
partial or complete remission (as opposed to 2 % from Still
et al.) [9]. In contrast to this, Sampaio-Neto et al., who studied
a small Brazilian population, demonstrated a better predictive
power at higher DiaRem scores although there was a disparity
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at the lowest DiaRem scores of 0–2 wherein <50 % experi-
enced complete remission (vs 61 % from Still et al.) [7, 10].
The causes of this disparity between different populations
are unclear, and the determination of such causes is beyond
the power of a retrospective study. However, it should be
noted that in terms of age (mean age 50.5 in Still et al. vs
51.0 years in our study), gender prevalence and BMI
(presurgical BMI 48.8 in Still et al. vs 45.3 kg/m2 in our
study), the population studied by Still et al. was similar [7,
8]. The most striking difference is the wider ethnic diversity in
our data, which reflects the London-wide population. Ninety-
seven percent of patients studied by Still et al. were white
Caucasian whilst this was true for only 61.1 % of this cohort.
Whilst this observation can only suggest a possible associa-
tion, it is not inconceivable that ethnic origin may play a role.
Previous studies have demonstrated that ethnicity can affect
susceptibility to developing T2DM [10, 12] as well as re-
sponse to diabetes medication, with Asians (who represented
10 % of our study population) doing worse than Caucasians
[7, 13]. Similarly, the difference in DiaRem performance not-
ed in the study of Lee et al. might be explained by the fact that
they were studying a Chinese population [8].
Table 1 Characteristics of
patients who underwent bariatric
surgery at the Imperial College
Weight Centre 2007 to 2014
Pre-surgery 1 year post-surgery P value










Weight mean (SD) (range) in kg 133.4 (23.4) (83–232) 94.3 (20.2) (54.0–181.0) <0.001
BMI mean (SD) (range) in kg/m2 45.3(7.1) (33.5–69.2) 32.9 (5.9) (29.2–52.9) <0.001
HbA1c mean (SD) (range) in % 8.2 (1.8) (5.1–16.4) 6.1 (1.0) (4.6–10.5) <0.001
Diabetic medication no. (%)
Metformin 220 (84.0) 151 (57.6) <0.0001
Sulphonylurea 58 (22.1) 2 (0.01) <0.0001
Other insulin-sensitizing agent 58 (22.1) 7 (0.02) <0.0001
Insulin 77 (29.4) 48 (18.3) <0.003






Table 2 Comparison of the DiaRem scores from the bariatric surgery population at Imperial Weight Centre (P < 0.0001 for trends in both CR/PR and
PR, Cochran-Armitage test) and from Still et al. [7], Aminian et al. [9], Lee et al. [8] and Sampaio-Neto et al. [10]





et al. (N = 70)
DiaRem score CR/PR no. (%) CR no. (%) CR/PR (%) CR (%) CR/PR (%) CR (%) CR (%)
0–2 19 (67.8) 19 (67.8) 88 61 86 100.0 45.7
3–7 37 (38.5) 35 (38.5) 64 32 78 85.3 42.8
8–12 17 (27.9) 12 (19.7) 23 10 30 43.5 11.4
13–17 4 (9.5) 3 (7.1) 11 5 27 38.1 0.0
18–22 8 (22.9) 4 (11.4) 2 0 20 27.9 0.0
Abbreviations: CR complete remission, PR partial remission
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However, there may be alternative causes for the dif-
ferences observed in our study. The DiaRem score is also
affected by prescribing practices. In the UK study popu-
lation, sulphonylureas and insulin-sensitizing drugs are
less commonly used than in the US population (22 vs
32 %, respectively, for sulphonylureas; 22 vs 31 % for
insulin-sensitizing agents) [7]. Furthermore, based on re-
cent medication surveys, insulin prescription is higher in
the UK than in the USA (23.3 vs 8.1 %, respectively) [14,
15]. These differences, driven by national guidelines, drug
licensing and historical practice, affect the DiaRem score
and, therefore, may limit the applicability of the score in
the UK population as well as other populations with pre-
scribing practices at variance to those in the USA.
This study has several limitations that should be noted.
Whilst it represents the largest cohort so far used to validate
the DiaRem score, the studied population remains too small to
support meaningful subgroup analyses of the different ethnic
groups. Furthermore, whilst this represents the first validation
of DiaRem within the UK population, the subject data came
from a small cohort treated at a single institution and it is
unclear whether the results are generalizable to the entire
British population.
The DiaRem score provides an easy-to-determine score for
predicting diabetes remission to aid decision-making for sur-
gery. Whilst predictive scores are more useful in the context of
assessing response within a large population, increasing pres-
sures on both finances and resources mandate the need for a
clinical test to guide both surgeons and patients. However, in
our population, use of the DiaRem score may falsely deter
patients with higher scores from surgery that would benefit a
significant proportion. These higher scoring DiaRem patients
represent a subpopulation who have generally worse or more
long-standing diabetes, and so potentially have the most to
gain by undergoing surgery.
A better predictive tool is required to assess patients placed
in the higher DiaRem score group. One previous criticism of
the DiaRem score is that it does not take into account duration
of diabetes [7–9]. Duration of T2DM has previously been
demonstrated to be a strong risk factor for remission of diabe-
tes as it may be a surrogate for pancreatic function [16]. This
variable was not included as part of the Still et al. multivariate
analysis, but determining duration of diabetes can be impre-
cise due to the absence of a systematic screening process in
most countries and the vague symptoms (or even absence of
symptoms) associated with this condition. In addition, whilst
the DiaRem score is simple to calculate, it fails to take directly
into account any of the postulated mechanisms of diabetes
remission such as elevated gut hormone [17] or bile acid se-
cretion [18]. Future prospective studies could evaluate the
predictive power of measurement of pre-surgical levels of
these mediators as well as investigate different ethnic groups
in larger numbers. A final limitation of any predictive score
that uses diabetes remission as an end point is that it overlooks
any significant improvement in both HbA1c and reduction in
medication. Whilst diabetes remission was observed in only
85 patients in this cohort, there was a large reduction in the
burden of medication (Table 2).
Conclusion
The DiaRem score, a model used to predict diabetes remission
following bariatric surgery, is less successful for the purposes
of predicting remission in the patients treated in this single
bariatric unit within the UK. Specifically, it is less useful at
predicting response in those who have higher DiaRem score.
This may reflect differences in ethnic diversity in the studied
populations, or differences in prescribing between countries.
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